6533b85bfe1ef96bd12bbeb9
RESEARCH PRODUCT
Neuronal effects of Sugammadex in combination with Rocuronium or Vecuronium.
Martin AldasoroAntonio IradiConstanza AldasoroMarc Gimeno-ragaJose Mª VilaSol Guerra-ojedaMª Dolores MauricioElena ObradorAdrian JordaSoraya L. VallesPatricia Marchiosubject
vecuroniumNecrosisEstrès oxidatiuPrimary Cell CulturerocuroniumCaspase 3NeuronesPharmacologySugammadexSugammadex03 medical and health sciences0302 clinical medicine030202 anesthesiologymedicineAnimalsHumansAndrostanolsRocuroniumCell damageNeuronsVecuronium BromideDose-Response Relationship DrugCaspase 3business.industryapoptosis.Apoptosis Inducing FactorCytochromes c030208 emergency & critical care medicineGeneral Medicinemedicine.diseaseneuronRatsDrug Combinationsmedicine.anatomical_structureGene Expression RegulationApoptosisToxicityNeuronNeuromuscular Blocking Agentsmedicine.symptombusinessResearch Papergamma-Cyclodextrinsmedicine.drugdescription
Rocuronium (ROC) and Vecuronium (VEC) are the most currently used steroidal non-depolarizing neuromuscular blocking (MNB) agents. Sugammadex (SUG) rapidly reverses steroidal NMB agents after anaesthesia. The present study was conducted in order to evaluate neuronal effects of SUG alone and in combination with both ROC and VEC. Using MTT, CASP-3 activity and Western-blot we determined the toxicity of SUG, ROC or VEC in neurons in primary culture. SUG induces apoptosis/necrosis in neurons in primary culture and increases cytochrome C (CytC), apoptosis-inducing factor (AIF), Smac/Diablo and Caspase 3 (CASP-3) protein expression. Our results also demonstrated that both ROC and VEC prevent these SUG effects. The protective role of both ROC and VEC could be explained by the fact that SUG encapsulates NMB drugs. In BBB impaired conditions it would be desirable to control SUG doses to prevent the excess of free SUG in plasma that may induce neuronal damage. A balance between SUG, ROC or VEC would be necessary to prevent the risk of cell damage.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-02-01 |